Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):183–191. doi: 10.1093/ehjqcco/qcx010

Table 2.

Presentation and in-hospital characteristics and discharge interventions of the study population

Patient characteristics Normal Weight (n = 5920) Overweight (n = 7982) Obese class I (n = 3837) Obese class II (n = 1192) Obese class III (n = 568) P-value
Presentation and in-hospital characteristics
Heart rate, bpm 74 (62–88) 74 (63–88) 75 (63–88) 77 (65–90) 78.5 (66–92) <0.001
Systolic blood pressure, mmHg 138 (116–158) 141 (120–162) 142 (122–163) 143 (122–164) 145 (121–164) <0.001
Signs of HF, number (%) 453 (7.7) 641 (8.0) 309 (8.1) 106 (8.9) 49 (8.6) 0.17
Initial haemoglobin, g/dL 13.5 (12.3–14.7) 14.0 (12.8–15.1) 14.0 (12.9–15.2) 13.9 (12.7–15.1) 13.5 (12.5–14.7) <0.001
Initial creatinine, mg/dL 1.0 (0.9–1.3) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 1.1 (0.9–1.3) <0.001
Initial troponin, xULN 1.2 (0.3–11.9) 1.0 (0.3–10.8) 1.0 (0.2–9.8) 1.0 (0.3–9.9) 1.4 (0.3–15.2) 0.005
LVEF, number (%) <0.001
 ≥50% 2661 (46.8) 3906 (50.8) 1908 (51.6) 563 (49.6) 303 (55.8)
 25–50% 2785 (49.0) 3515 (45.8) 1665 (45.0) 546 (48.1) 225 (41.4)
 <25% 224 (3.9) 239 (3.1) 100 (2.7) 23 (2.0) 12 (2.2)
Multi-vessel coronary disease, number (%) 4018 (68.4) 5479 (69.1) 2623 (68.8) 785 (66.4) 356 (63.1) 0.10
Overall reperfusion therapy 5361 (96.2) 7157 (95.8) 3440 (95.3) 1081 (96.4) 527 (97.4) 0.41
Primary PCI 4922 (89.1) 6527 (88.1) 3103 (86.7) 985 (88.9) 484 (90.1) 0.03
Door to balloon time (minutes) 64.0 (49.0–81.0) 63.0 (48.0–79.0) 64.0 (48.0–80.0) 64.0 (50.5–82.0) 64.0 (48.0–81.5) 0.72
In-hospital CABG, number (%) 329 (5.6) 605 (7.6) 288 (7.5) 70 (5.9) 24 (4.2) 0.02
In-hospital cardiogenic shock, number (%) 289 (4.9) 310 (3.9) 140 (3.7) 39 (3.3) 20 (3.5) <0.001
In-hospital major bleeding, number (%) 723 (12.2) 801 (10.0) 365 (9.5) 127 (10.7) 71 (12.5) <0.001
Aspirin within 24 h, number (%) 5788 (98.9) 7787 (98.9) 3747 (98.9) 1160 (98.9) 553 (99.1) 0.91
P2Y12 receptor inhibitor within 24 h, number (%) 5417 (91.5) 7240 (90.7) 3457 (90.1) 1097 (92.0) 536 (94.4) 0.65
Statin within 24 h, number (%) 4154 (72.7) 5611 (72.9) 2709 (72.9) 856 (75.0) 418 (75.3) 0.22
Discharge interventions
Aspirin, number (%) 5747 (98.9) 7748 (99.0) 3719 (98.9) 1157 (99.1) 545 (98.4) 0.97
P2Y12 receptor inhibitor, number (%) 5552 (94.2) 7365 (92.7) 3531 (92.4) 1116 (93.9) 534 (94.9) 0.04
Statin, number (%) 5440 (94.6) 7349 (94.9) 3552 (95.0) 1108 (96.1) 518 (94.5) 0.15
Beta blocker, number (%) 5413 (97.4) 7408 (97.8) 3587 (97.5) 1112 (97.1) 532 (97.8) 0.97
ACE inhibitor/ARB, number (%) 4200 (76.8) 5823 (78.3) 2928 (81.1) 909 (81.3) 446 (82.9) <0.001
Aldosterone antagonist, number (%) 235 (4.1) 331 (4.2) 180 (4.8) 61 (5.2) 28 (5.1) 0.02
Cardiac rehabilitation referral, number (%) 4665 (84.7) 6440 (85.0) 3126 (85.3) 973 (84.6) 454 (85.3) 0.58

Data represented as median (IQR) or number (%). P-value was calculated by comparing only non-missing row values; all P-values are 5-group comparisons. BMI (kg/m2) categories are according to the World Health Organization classification: normal weight (18.5–24.9), overweight (25–29.9), class I obese (30–34.9), class II obese (35–39.9), and class III obese (≥40).

ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BPM, beats per minute; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; HF, heart failure; PCI, percutaneous coronary intervention; ULN, upper limit of normal; BMI, body mass index.